APRESSINE (Apressinum; synonym: Hydralazini Hydrochloridum, Hypralazine, Apresoline; GFH, joint venture. B) — antihypertensive. 1-Gidrazinoftalazina hydrochloride; With 8 H 8 N 4 HCl:
White crystal powder, we will dissolve in water. It is well soaked up from went. - kish. path.
And. causes permanent lowering of arterial pressure, increases the systolic and minute volume of heart and a renal blood stream, reduces a tone of vessels of a brain. Has anti-hypoxemic effect. And. reduces also blood pressure caused by reflex influences, weakens effect of biogenic pressor substances (Hypertensinum, sympathomimetic amines, etc.); does not render a direct impact on unstriated muscles of peripheral vessels and vessels of internals. Main mechanism of hypotensive action And. it is not found out. Action And. develops slowly and begins in 30 — 40 min. after introduction.
Drug is used at an idiopathic hypertensia, it is preferential at early stages, and at an eclampsia. Appoint inside after food, since 0,01 g 2 — 4 times a day. At good tolerance the dose is gradually increased to 0,02 — 0,025 g by the Highest doses: one-time — 0,1 g, daily — 0,3 g. A course of treatment — 2 — 4 weeks, at the end of a course gradually reduce a dose. Repeated courses are conducted in 3 — 5 months. For strengthening of effect and the prevention of by-effects And. appoint in a combination with other hypotensive drugs and gangliolitika that gives the chance to apply smaller doses.
At use And. the headache, tachycardia, pains in heart, nausea, vomiting, perspiration, conjunctivitis, rashes, etc. can be observed. By-effects can be eliminated by means of antihistaminic and sedatives (Dimedrol, aminazine).
And. it is contraindicated at heart failure, stenocardia, hron, diseases of kidneys, an angiosclerosis of a brain and heart.
Form of release: powder and tablets on 0,01 and 0,025 g. To store in well corked container.
See also Antihypertensives .
Bibliography: Bondarenko B. B. Peculiar current of a gidralazinovy syndrome, Klin, medical, t. 43, No. 3, page 138, 1965, bibliogr.; Votchal B. E. Sketches of clinical pharmacology, page 104, M., 1965; Mashkovsky M. D. Pharmaceuticals, p.1, page 363, M., 1972; A b 1 a d B. A study of the mechanism of the hemodynamic effects of hydralazine in man, Copenhagen, 1963; Leodolter S. o. The mechanism of noradrenaline depletion by hydrazinophthalazines in the rat heart, Europ. J. Pharmacol., v. 13, p. 188, 1971, bibliogr.
A. I. Beketov.